Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 54 articles: HTML format Text format

Single Articles

June 2018
1. DE KOCK L, Fahiminiya S, Fiset PO, Astigarraga I, et al
   Infantile Pulmonary Teratoid Tumor.
   N Engl J Med. 2018;378:2238-2240.
   PubMed     Text format    
   
   
   
2. SCLAFANI A, VanderLaan P
   Lymphangioleiomyomatosis.
   N Engl J Med. 2018;378:2224.
   PubMed     Text format    
   
   
   May 2018
3. SCHILLER JH
   A New Standard of Care for Advanced Lung Cancer.
   N Engl J Med. 2018;378:2135-2137.
   PubMed     Text format    
   
   
   
4. JEMAL A, Miller KD, Ma J, Siegel RL, et al
   Higher Lung Cancer Incidence in Young Women Than Young Men in the United States.
   N Engl J Med. 2018;378:1999-2009.
   PubMed     Text format     Abstract available
   
   
   
5. ELMORE SNC
   p53 and Me.
   N Engl J Med. 2018;378:1962-1963.
   PubMed     Text format    
   
   
   April 2018
6. GANDHI L, Rodriguez-Abreu D, Gadgeel S, Esteban E, et al
   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
   N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801005.
   PubMed     Text format     Abstract available
   
   
   
7. FORDE PM, Chaft JE, Smith KN, Anagnostou V, et al
   Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
   N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1716078.
   PubMed     Text format     Abstract available
   
   
   
8. HELLMANN MD, Ciuleanu TE, Pluzanski A, Lee JS, et al
   Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
   N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801946.
   PubMed     Text format     Abstract available
   
   
   
9. MAMDANI H, Grethlein SJ
   Pulmonary Metastases from Chondroblastic Osteosarcoma.
   N Engl J Med. 2018;378:1429.
   PubMed     Text format    
   
   
   March 2018
10. CHOI JY, Choi YJ, Shin SW
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1262.
    PubMed     Text format    
    
    
    
11. ROCA E, Amoroso V, Berruti A
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-2.
    PubMed     Text format    
    
    
    
12. WARD MC, Prabhu RS, Burri SH
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261.
    PubMed     Text format    
    
    
    
13. 
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-1263.
    PubMed     Text format    
    
    
    
14. WEINSTOCK M, Vaidya A, El-Chemaly S, Godleski J, et al
    The Verge of Collapse.
    N Engl J Med. 2018;378:e18.
    PubMed     Text format    
    
    
    
15. 
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868-870.
    PubMed     Text format    
    
    
    
16. SANTONI M, Battelli N, Buti S
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:869.
    PubMed     Text format    
    
    
    
17. COPUR MD, Gauchan D, Ramaekers R
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868.
    PubMed     Text format    
    
    
    January 2018
18. POPAT S
    Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:192-193.
    PubMed     Text format    
    
    
    November 2017
19. SORIA JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al
    Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Nov 18. doi: 10.1056/NEJMoa1713137.
    PubMed     Text format     Abstract available
    
    
    
20. SOHAL SS, Walers EH
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998-9.
    PubMed     Text format    
    
    
    
21. REN C, Han C, Wang D
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998.
    PubMed     Text format    
    
    
    
22. KWON HW, Ham SY, Shin SW
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1997-8.
    PubMed     Text format    
    
    
    
23. RIZVI NA, Peters S
    Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1986-1988.
    PubMed     Text format    
    
    
    
24. 
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1999.
    PubMed     Text format    
    
    
    September 2017
25. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
    Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Sep 8. doi: 10.1056/NEJMoa1709937.
    PubMed     Text format     Abstract available
    
    
    August 2017
26. RECK M, Rabe KF
    Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:849-861.
    PubMed     Text format    
    
    
    June 2017
27. CARBONE DP, Reck M, Paz-Ares L, Creelan B, et al
    First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:2415-2426.
    PubMed     Text format     Abstract available
    
    
    
28. PETERS S, Camidge DR, Shaw AT, Gadgeel S, et al
    Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Jun 6. doi: 10.1056/NEJMoa1704795.
    PubMed     Text format     Abstract available
    
    
    
29. ROBLES AI, Zenklusen JC
    Seeing the Forest through the Phylogenetic Tree.
    N Engl J Med. 2017;376:2190-2191.
    PubMed     Text format    
    
    
    May 2017
30. NISHINO M, Hatabu H
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1992-3.
    PubMed     Text format    
    
    
    
31. YIN Y, Li J
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993.
    PubMed     Text format    
    
    
    
32. 
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993-4.
    PubMed     Text format    
    
    
    
33. ZHANG BM, Aleshin A, Lin CY, Ford J, et al
    IDH2 Mutation in a Patient with Metastatic Colon Cancer.
    N Engl J Med. 2017;376:1991-2.
    PubMed     Text format    
    
    
    April 2017
34. JAMAL-HANJANI M, Wilson GA, McGranahan N, Birkbak NJ, et al
    Tracking the Evolution of Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Apr 26. doi: 10.1056/NEJMoa1616288.
    PubMed     Text format     Abstract available
    
    
    March 2017
35. DEFILIPPIS EM, Vaidya A, Ramani S, French C, et al
    Under Pressure.
    N Engl J Med. 2017;376:e23.
    PubMed     Text format    
    
    
    
36. SORSCHER S
    Pembrolizumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:996-7.
    PubMed     Text format    
    
    
    
37. 
    Pembrolizumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:997.
    PubMed     Text format    
    
    
    February 2017
38. MAOZ A, Rennert G, Gruber SB
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    
    
    
    
39. RECH AJ, Vonderheide RH
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    
    
    
    
40. ROSENBERG SA, Tran E, Robbins PF
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    
    
    
    
41. MOK TS, Wu YL, Ahn MJ, Garassino MC, et al
    Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:629-640.
    PubMed     Text format     Abstract available
    
    
    December 2016
42. TRAN E, Robbins PF, Lu YC, Prickett TD, et al
    T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
    N Engl J Med. 2016;375:2255-2262.
    PubMed     Text format     Abstract available
    
    
    October 2016
43. JOHNSON BE
    Divide and Conquer to Treat Lung Cancer.
    N Engl J Med. 2016.
    PubMed     Text format    
    
    
    
44. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
45. CHOY E, Hornicek FJ, Chen YL, Rosenthal DI, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 26-2016. A 28-Year-Old Woman with Back Pain and a Lesion in the Lumbar Spine.
    N Engl J Med. 2016;375:779-88.
    PubMed     Text format    
    
    
    July 2016
46. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    PubMed     Text format    
    
    
    June 2016
47. SEQUIST LV, Soria JC, Camidge DR
    Update to Rociletinib Data with the RECIST Confirmed Response Rate.
    N Engl J Med. 2016;374:2296-7.
    PubMed     Text format    
    
    
    May 2016
48. SWANTON C, Govindan R
    Clinical Implications of Genomic Discoveries in Lung Cancer.
    N Engl J Med. 2016;374:1864-73.
    PubMed     Text format    
    
    
    
49. BORDI P, Del Re M, Tiseo M
    Crizotinib Resensitization by Compound Mutation.
    N Engl J Med. 2016;374:1790.
    PubMed     Text format    
    
    
    
50. SHAW AT, Engelman JA
    Crizotinib Resensitization by Compound Mutation.
    N Engl J Med. 2016;374:1790-1.
    PubMed     Text format    
    
    
    February 2016
51. GYAWALI B, Ota A, Ando Y
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:493.
    PubMed     Text format    
    
    
    
52. HASEGAWA T, Uno H, Wei LJ
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:492-3.
    PubMed     Text format    
    
    
    
53. BORGHAEI H, Brahmer J
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:493-4.
    PubMed     Text format    
    
    
    January 2016
54. SHAW AT, Friboulet L, Leshchiner I, Gainor JF, et al
    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    N Engl J Med. 2016;374:54-61.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: